Company / Return on Equity (ROE)
Ventyx Biosciences, Inc. Return on Equity (ROE) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-53.2%
FY2024
5-year range
-79.1% / -30.0%
FY2021-FY2024
Trend
+32.8%
vs FY2023
Sector context
#137 of 190
Health Care
What the data says
Ventyx Biosciences, Inc. reports negative total equity of -53.2% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-53.2% in FY2024 with a 3-year CAGR of -23.2%.
Declined from -30.6% to -53.2% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -23.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#137 of 190 in Health CareTop 72% of 190This company -53.2% Sector average -29.0%
▼
-83.7% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 32.8% year-over-year.
- Currently 24.2pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -53.2% | +32.8% |
| FY2023 | -79.1% | -158.2% |
| FY2022 | -30.6% | -2.1% |
| FY2021 | -30.0% | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026